Last checked at 9 Mar 2021 17:48
SMITH & NEPHEW PLC
9 March 2021
NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.
1. VESTING OF SHARE AWARDS UNDER THE GLOBAL SHARE PLAN 2010 AND 2020
On 7 March 2021, the following awards of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") vested under the Smith & Nephew Global Share Plan 2010.
i. VESTING ON 7 MARCH 2021 OF 2018 PERFORMANCE SHARE PROGRAMME AWARDS MADE UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2010:
The awards were granted under the Global Share Plan 2010 on 7 March 2018 and as announced on 3 February 2021, vested at 47% of target and settled on 8 March 2021 being the first business date after the third anniversary of the awards. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares.
The following relates to individuals included in the below notification:
Reason for the notification |
| |||||||
Initial notification /Amendment | Initial notification |
| ||||||
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| |||||||
Name | Smith & Nephew plc |
| ||||||
LEI | 213800ZTMDN8S67S1H61 |
| ||||||
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| |||||||
Description of the financial instrument, type of instrument
| Smith & Nephew plc ordinary shares of USD 0.20 each
|
| ||||||
Identification code | ISIN: GB0009223206 |
| ||||||
Nature of the transaction | Vesting of Smith & Nephew Global Share Plan 2010 Performance Share Programme awards granted on 7 March 2018. |
| ||||||
Date of Transaction | 2021 - 03 - 08 |
| ||||||
Place of Transaction | London Stock Exchange (XLON) |
| ||||||
Name (Position) |
Status | Price (£) | Volume | Aggregated information | Total Ordinary Share Holding following the transaction * | Total Ordinary Share Holding as a % of the Company's ISC following the transaction * | ||
Bradley Cannon (President Sports Medicine & ENT) | PDMR | 13.4385
| 8,123 (of which 3,616 were sold and 4,507 retained) | N/A Single Transaction | 69762.76313 ordinary shares (including 2,101.64550 in ADS') | 0.00788%
| ||
Phil Cowdy (Chief Business Development & Corporate Affairs Officer) | PDMR | 13.4385
| 3,869 (of which 1,825 were sold and 2,044 retained) | N/A Single Transaction | 37,044.19975 ordinary shares | 0.00419%
| ||
Elga Lohler (Chief HR Officer) | PDMR | 13.4385
| 6,185 (of which 2,443 were sold and 3,742 retained) | N/A Single Transaction | 93,097.00000 ordinary shares (including 3,105.00000 in ADS') | 0.01052%
| ||
Catheryn O'Rourke (Chief Legal & Compliance Officer) | PDMR | 13.4385
| 6,129 (of which 2,089 were sold and 4,040 retained) | N/A Single Transaction | 66,886.23565 ordinary shares (including 5,818.25734 in ADS') | 0.00756%
| ||
Vasant Padmanabhan (President Research & Development) | PDMR | 13.4385
| 6,966 (of which 2,365 were sold and 4,601 retained) | N/A Single Transaction | 49,890.00000 ordinary shares | 0.00564%
| ||
Susan Swabey (Company Secretary) | PDMR | 13.4385
| 2,727 (of which 1,287 were sold and 1,440 retained) | N/A Single Transaction | 45,759.83952 ordinary shares | 0.00517%
| ||
* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.
ii. FINAL VESTING ON 7 MARCH 2021 OF 2018 EQUITY INCENTIVE PROGRAMME AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2010:
The awards were granted under the Global Share Plan 2010 on 7 March 2018. One third of the Shares vested on 7 March 2019, a further third vested on 7 March 2020 and the final third vested on 7 March 2021. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares.
The following relates to individuals included in the below notification:
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument
| Smith & Nephew plc ordinary shares of USD 0.20 each
|
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Final vesting of Equity Incentive Programme awards granted on 7 March 2018 under the Smith & Nephew Global Share Plan 2010. |
Date of Transaction | 2021 - 03 - 08 |
Place of Transaction | London Stock Exchange (XLON) |
Name (Position) |
Status | Price (£) | Volume | Aggregated information | Total Ordinary Share Holding following the transaction * | Total Ordinary Share Holding as a % of the Company's ISC following the transaction * |
Bradley Cannon (President Sports Medicine & ENT) | PDMR | 13.4385 | 5,240 (of which 2,333 were sold and 2,907 retained) | N/A Single Transaction | 72,669.76313 ordinary shares (including 2,101.64550 in ADS') | 0.00821%
|
Phil Cowdy (Chief Business Development & Corporate Affairs Officer) | PDMR | 13.4385 | 3,089 (of which 1,457 were sold and 1,632 retained) | N/A Single Transaction | 38,676.19975 ordinary shares | 0.00437%
|
Elga Lohler (Chief HR Officer) | PDMR | 13.4385 | 4,389 (of which 1,734 were sold and 2,655 retained) | N/A Single Transaction | 95,752.00000 ordinary shares (including 3,105.00000 in ADS') | 0.01082%
|
Catheryn O'Rourke (Chief Legal & Compliance Officer) | PDMR | 13.4385 | 4,350 (of which 1,483 were sold and 2,867 retained) | N/A Single Transaction | 69,753.23565 ordinary shares (including 5,818.25734 in ADS') | 0.00788%
|
Vasant Padmanabhan (President Research & Development) | PDMR | 13.4385 | 4,494 (of which 1,526 were sold and 2,968 retained) | N/A Single Transaction | 52,858.00000 ordinary shares | 0.00597%
|
Susan Swabey (Company Secretary) | PDMR | 13.4385 | 1,936 (of which 914 were sold and 1,022 retained) | N/A Single Transaction | 46,781.83952 ordinary shares | 0.00529%
|
* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.
iii. PARTIAL VESTING ON 7 MARCH 2021 OF 2019 EQUITY INCENTIVE PROGRAMME AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2010:
The awards were granted under the Global Share Plan 2010 on 7 March 2019. One third of the Shares vested on 7 March 2020, a further third vested on 7 March 2021 and the final third will vest on 7 March 2022. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares.
The following relates to individuals included in the below notification:
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument
| Smith & Nephew plc ordinary shares of USD 0.20 each
|
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Partial vesting of Equity Incentive Programme awards granted on 7 March 2019 under the Smith & Nephew Global Share Plan 2010. |
Date of Transaction | 2021 - 03 - 08 |
Place of Transaction | London Stock Exchange (XLON) |
Name (Position) |
Status | Price (£) | Volume | Aggregated information | Total Ordinary Share Holding following the transaction * | Total Ordinary Share Holding as a % of the Company's ISC following the transaction * |
Bradley Cannon (President Sports Medicine & ENT) | PDMR | 13.4385 | 4,859 (of which 2,162 were sold and 2,697 retained) | N/A Single Transaction | 75,366.76313 ordinary shares (including 2,101.64550 in ADS') | 0.00852%
|
Phil Cowdy (Chief Business Development & Corporate Affairs Officer) | PDMR | 13.4385 | 2,423 (of which 1,143 were sold and 1,280 retained) | N/A Single Transaction | 39,956.19975 ordinary shares | 0.00452%
|
Mark Gladwell (President Operations & GBS) | PDMR | 13.4385 | 2,268 (of which 1,070 were sold and 1,198 retained) | N/A Single Transaction | 2,801.44339 ordinary shares | 0.00032%
|
Melissa Guerdan (Chief Quality & Regulatory Affairs Officer) | PDMR | 13.4385 | 1,927 (of which 658 were sold and 1,269 retained) | N/A Single Transaction | 2,551.42336 ordinary shares | 0.00029%
|
Skip Kiil (President Orthopaedics) | PDMR | 13.4385 | 6,143 (of which 2,350 were sold and 3,793 retained) | N/A Single Transaction | 3,793.53744 ordinary shares | 0.00043%
|
Elga Lohler (Chief HR Officer) | PDMR | 13.4385 | 4,608 (of which 1,819 were sold and 2,789 retained) | N/A Single Transaction | 98,541.00000 ordinary shares (including 3,105.00000 in ADS') | 0.01114%
|
Catheryn O'Rourke (Chief Legal & Compliance Officer) | PDMR | 13.4385 | 4,471 (of which 1,524 were sold and 2,947 retained) | N/A Single Transaction | 72,700.23565 ordinary shares (including 5,818.25734 in ADS') | 0.00822%
|
Vasant Padmanabhan (President Research & Development) | PDMR | 13.4385 | 4,167 (of which 1,414 were sold and 2,753 retained) | N/A Single Transaction | 55,611.00000 ordinary shares | 0.00628%
|
Susan Swabey (Company Secretary) | PDMR | 13.4385 | 1,699 (of which 801 were sold and 898 retained) | N/A Single Transaction | 47,679.83952 ordinary shares | 0.00539%
|
* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.
2. SUPPLEMENTARY AWARDS GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020 FOR THE 2018 PERFORMANCE SHARE PROGRAMME AWARDS:
The Performance Share Programme is designed to incentivise senior management for performance delivered over a three-year period. The impact of COVID-19 in 2020 has had, and will have, a significant impact on the Performance Share Programme's ability to recognise performance delivered in preceding and consequent years. Reflecting these considerations, the following awards of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") were granted under the Smith & Nephew Global Share Plan 2020 ("Supplementary Awards") on 8 March 2021 to the PDMRs listed below. No Supplementary Award has been granted to either the Chief Executive Officer or the Chief Financial Officer. Each Supplementary Award is linked to a Performance Share Programme award granted in 2018, 2019 and 2020 so that a minimum vesting of between 50% and 70% of the original award at target will be achieved. If the 2019 or, as relevant, 2020 Performance Share Programme award vests at 70% of target or more, the whole of the Supplementary Award lapses. The Supplementary Award represents 25% to 35% of the maximum award available to participants.
i. SUPPLEMENTARY AWARDS GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020 FOR THE 2018 PERFORMANCE SHARE PROGRAMME AWARDS:
As announced on 3 February 2021, 47% of the target 2018 Performance Share Programme award vested. Therefore a conditional share award equivalent to 23% of the original 2018 Performance Share Programme award has been granted to the PDMRs listed below and will vest 100% on 16 March 2021. No price is payable either upon grant or vesting of the awards.
The following relates to individuals included in the below notification:
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument
| Smith & Nephew plc Ordinary Shares of USD 0.20 each
|
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Grant of supplementary conditional share award on 8 March 2021 under the Smith & Nephew Global Share Plan 2020 relating to the 2018 Performance Share Programme awards. |
Date of Transaction | 2021 - 03 - 08 |
Place of Transaction | Grant took place outside a trading venue |
Name (Position) | Status | Price (£) | Volume(s)* | Aggregated information |
Bradley Cannon (President Sports Medicine & ENT) | PDMR | Nil | 3,740 | N/A Single Transaction |
Phil Cowdy (Chief Business Development & Corporate Affairs Officer) | PDMR | Nil | 1,781 | N/A Single Transaction |
Elga Lohler (Chief HR Officer) | PDMR | Nil | 2,848 | N/A Single Transaction |
Catheryn O'Rourke (Chief Legal & Compliance Officer) | PDMR | Nil | 2,823 | N/A Single Transaction |
Vasant Padmanabhan (President Research & Development) | PDMR | Nil | 3,207 | N/A Single Transaction |
Susan Swabey (Company Secretary) | PDMR | Nil | 1,255 | N/A Single Transaction |
Total: | - | Nil | 15,654 | - |
* The number of shares under the award was calculated by granting 23% of the original target number of shares awarded under the related 2018 Performance Share Programme award. The calculation of the grant was by reference to a share price of 1,291p per share, being the Company share price as at 6 March 2018, the Mid-Market Quote the day before grant. No more than a total of 70% of the target number of shares originally awarded under the Performance Share Programme shall vest when combining the vesting of the Supplementary Award and its linked Performance Share Programme award.
ii. SUPPLEMENTARY AWARDS GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020 FOR THE 2019 PERFORMANCE SHARE PROGRAMME AWARDS:
A conditional share award equivalent to 50% of the 2019 Performance Share Programme award has been granted to the PDMRs listed below and will vest on 7 March 2022, subject to the limit which is no more than a total of 70% of the target number of shares under the 2019 Performance Share Programme award will vest when combining the vesting of the Supplementary Award and its linked Performance Share Programme award. Any part of the Supplementary Award that would cause this limit to be exceeded will lapse. No price is payable either upon grant or vesting of the awards.
The following relates to individuals included in the below notification:
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument
| Smith & Nephew plc Ordinary Shares of USD 0.20 each
|
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Grant of supplementary conditional share award on 8 March 2021 under the Smith & Nephew Global Share Plan 2020 relating to the 2019 Performance Share Programme awards. |
Date of Transaction | 2021 - 03 - 08 |
Place of Transaction | Grant took place outside a trading venue |
Name (Position) | Status | Price (£) | Volume(s)* | Aggregated information |
Bradley Cannon (President Sports Medicine & ENT) | PDMR | Nil | 7,696 | N/A Single Transaction |
Phil Cowdy (Chief Business Development & Corporate Affairs Officer) | PDMR | Nil | 5,641 | N/A Single Transaction |
Simon Fraser (President Advanced Wound Management) | PDMR | Nil | 6,791 | N/A Single Transaction |
Mark Gladwell (President Operations & GBS) | PDMR | Nil | 6,581 | N/A Single Transaction |
Melissa Guerdan (Chief Quality & Regulatory Affairs Officer) | PDMR | Nil | 6,291 | N/A Single Transaction |
Skip Kiil (President Orthopaedics) | PDMR | Nil | 9,722 | N/A Single Transaction |
Elga Lohler (Chief HR Officer) | PDMR | Nil | 6,680 | N/A Single Transaction |
Catheryn O'Rourke (Chief Legal & Compliance Officer) | PDMR | Nil | 6,495 | N/A Single Transaction |
Vasant Padmanabhan (President Research & Development) | PDMR | Nil | 6,595 | N/A Single Transaction |
Susan Swabey (Company Secretary) | PDMR | Nil | 2,446 | N/A Single Transaction |
Total: | - | Nil | 64,938 | - |
* This is the maximum number of shares that may vest under the award, calculated by granting 50% of the original target number of shares granted under the related 2019 Performance Share Programme award. The calculation of the grant was by reference to a share price of 1,462.5p per share, being the Company share price as at 6 March 2019, the Mid-Market Quote the day before grant. The number of shares that shall vest will be reduced as necessary to ensure that no more than a total of 70% of the target number of shares originally awarded under the Performance Share Programme shall vest when combining the vesting of the Supplementary Award and its linked Performance Share Programme award.
iii. SUPPLEMENTARY AWARDS GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020 FOR THE 2020 PERFORMANCE SHARE PROGRAMME AWARDS:
A conditional share award equivalent to 50% of the 2020 Performance Share Programme award has been granted and will vest on 9 March 2023, subject to the limit which is that no more than a total of 70% of the target number of shares under the 2020 Performance Share Programme award will vest when combining the vesting of the Supplementary Award and its linked Performance Share Programme award. Any part of the Supplementary Award that would cause this limit to be exceeded will lapse. No price is payable either upon grant or vesting of the awards.
The following relates to individuals included in the below notification:
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument
| Smith & Nephew plc Ordinary Shares of USD 0.20 each
|
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Grant of supplementary conditional share award on 8 March 2021 under the Smith & Nephew Global Share Plan 2020 relating to the 2020 Performance Share Programme Awards. |
Date of Transaction | 2021 - 03 - 08 |
Place of Transaction | Grant took place outside a trading venue |
Name (Position) | Status | Price (£) | Volume(s)* | Aggregated information |
Bradley Cannon (President Sports Medicine& ENT) | PDMR | Nil | 7,406 | N/A Single Transaction |
Phil Cowdy (Chief Business Development & Corporate Affairs Officer) | PDMR | Nil | 4,965 | N/A Single Transaction |
Myra Eskes (President APAC Region) | PDMR | Nil | 7,348 | N/A Single Transaction |
Simon Fraser (President Advanced Wound Management) | PDMR | Nil | 6,407 | N/A Single Transaction |
Mark Gladwell (President Operations & GBS) | PDMR | Nil | 6,620 | N/A Single Transaction |
Melissa Guerdan (Chief Quality & Regulatory Affairs Officer) | PDMR | Nil | 6,113 | N/A Single Transaction |
Skip Kiil (President Orthopaedics) | PDMR | Nil | 9,172 | N/A Single Transaction |
Elga Lohler (Chief HR Officer) | PDMR | Nil | 6,618 | N/A Single Transaction |
Catheryn O'Rourke (Chief Legal & Compliance Officer) | PDMR | Nil | 6,434 | N/A Single Transaction |
Vasant Padmanabhan (President Research & Development) | PDMR | Nil | 6,409 | N/A Single Transaction |
Susan Swabey (Company Secretary) | PDMR | Nil | 2,206 | N/A Single Transaction |
Total: | - | Nil | 69,698 | - |
* This is the maximum number of shares that may vest under the award, calculated by granting 50% of the original target number of shares granted under the related 2020 Performance Share Programme award. The calculation of the grant was by reference to a share price of 1,661.5p per share, being the Company share price as at 20 May 2020, the Mid-Market Quote the day before grant. The number of shares that shall vest will be reduced as necessary to ensure that no more than a total of 70% of the target number of shares originally awarded under the Performance Share Programme shall vest when combining the vesting of the Supplementary Award and its linked Performance Share Programme award.
3. AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2020
On 9 March 2021 the following awards of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") were granted under the Smith & Nephew Global Share Plan 2020. The awards have been made in London and are based on the closing Share price on the London Stock Exchange on 8 March 2021 of £13.65.
i. EQUITY INCENTIVE PROGRAMME AWARDS GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020:
The awards will normally vest in equal annual tranches over three years following the award date subject to continued achievement of objectives and employment. In the event that objectives are not met in any of the three years, the portion of shares due to vest on the following anniversary will lapse. Participants will receive an additional number of shares equivalent to the amount of dividend payable per vested share during the relevant performance period.
The following relates to individuals included in the below notification:
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument
| Smith & Nephew plc Ordinary Shares of USD 0.20 each
|
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Equity Incentive Programme awards granted on 9 March 2021 under the Smith & Nephew Global Share Plan 2020. |
Date of Transaction | 2021 - 03 - 09 |
Place of Transaction | Grant took place outside a trading venue |
Name (Position) | Status | Price (s) | Volume(s) | Aggregated information |
Bradley Cannon (President Sports Medicine & ENT) | PDMR | £13.65 | 19,632 | N/A Single Transaction |
Peter Coenen (President EMEA Region) | PDMR | £13.65 | 4,908 | N/A Single Transaction |
Phil Cowdy (Chief Business Development & Corporate Affairs Officer) | PDMR | £13.65 | 15,744 | N/A Single Transaction |
Myra Eskes (President APAC Region) | PDMR | £13.65 | 17,131 | N/A Single Transaction |
Simon Fraser (President Advanced Wound Management) | PDMR | £13.65 | 14,233 | N/A Single Transaction |
Mark Gladwell (President Operations & GBS) | PDMR | £13.65 | 19,809 | N/A Single Transaction |
Melissa Guerdan (Chief Quality & Regulatory Affairs Officer) | PDMR | £13.65 | 13,844 | N/A Single Transaction |
Skip Kiil (President Orthopaedics) | PDMR | £13.65 | 20,377 | N/A Single Transaction |
Elga Lohler (Chief HR Officer) | PDMR | £13.65 | 17,543 | N/A Single Transaction |
Catheryn O'Rourke (Chief Legal & Compliance Officer) | PDMR | £13.65 | 15,516 | N/A Single Transaction |
Vasant Padmanabhan (President Research & Development) | PDMR | £13.65 | 14,546 | N/A Single Transaction |
Susan Swabey (Company Secretary) | PDMR | £13.65 | 6,917 | N/A Single Transaction |
ii. CONDITIONAL SHARE AWARDS GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020:
The awards will normally vest a third on the first anniversary of grant, a third on the second anniversary of grant and the final third will vest on the third anniversary of grant subject to continued achievement of objectives and employment.
The following relates to individuals included in the below notification:
Reason for the notification | |
Initial notification /Amendment | Initial notification |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
Name | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
Description of the financial instrument, type of instrument
| Smith & Nephew plc Ordinary Shares of USD 0.20 each
|
Identification code | ISIN: GB0009223206 |
Nature of the transaction | Conditional share awards granted on 9 March 2021 under the Smith & Nephew Global Share Plan 2020. |
Date of Transaction | 2021 - 03 - 09 |
Place of Transaction | Grant took place outside a trading venue |
Name (Position) |
Status | Price (s) | Volume(s) | Aggregated information |
Mark Gladwell (President Operations & GBS) | PDMR | £13.65 | 30,476 | N/A Single Transaction |
Skip Kiil (President Orthopaedics) | PDMR | £13.65 | 37,049 | N/A Single Transaction |
Susan Swabey
Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477410